Chief of the leukemia service and professor of oncology at the Roswell Park Comprehensive Cancer Center
The Potential of CAR T-Cell Therapy in Adult ALL
Eunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.
The Use of Clinical Endpoints in the ZUMA-3 Trial
Bijal Shah, MD, MS, and Eunice Wang, MD, discussed the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy.
Safety and Efficacy of the ZUMA-3 Trial
Bijal Shah, MD, MS, and Eunice Wang, MD, discuss efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and review key safety data.
ZUMA Trial of CAR T-Cell Therapy in R/R ALL
Eunice Wang, MD, and Bijal Shah, MD, MS, discuss the overall study design and patient population of the ZUMA-3 trial of CAR T-cell therapy in adult patients with R/R ALL.
Using MRD to Monitor CAR T Response in ALL
Eunice Wang, MD, and Bijal Shah, MD, MS, discussed the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.
The Role of CAR-T in the ALL Treatment Landscape
Eunice Wang, MD and Bijal Shah, MD, MS, discuss novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.
